FDA Pazdur's Opdivo Love Affair And Other Adventures
This article was originally published in Scrip
Executive Summary
This year's Biopharma Congress conference in Washington had something for everyone – debates on the current drug pricing atmosphere, discussions about what's missing in the House-passed 21st Century Cures Act that may be included in the Senate's version of the legislation and an update about the status of those pending FDA biosimilars guidances, which was essentially to confirm they're still pending.
You may also be interested in...
Kite’s Axi-Cel CAR-T: No Adcomm, No Problem
Next CAR-T in line at US FDA, Kite’s axicabtagene ciloleucel, looks headed toward an early approval with the agency confirming no panel will be scheduled, according to the firm. But the company and FDA may have benefited from an advisory committee review.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.